13. Hart PA, Topazian MD, Witzig TE et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–1615.
14. Yoshikawa M, Muro Y, Ogawa-Momohar, M.A. case with overlapping features of IgG4-related autoimmune pancreatitis, Sjögren's syndrome and anti-aminoacyl--tRNA synthetase syndrome. Mod Rheumatol Case Rep. 2021 Jan;5(1):82-86. doi: 10.1080/24725625.2020.1816675.,
15. Wang L, Zhang P, Wang M et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther2018; 20:65. doi:10.1186/s13075-018-1567-2 pmid:29636109
16. Omar D, Chen Y, Cong Y, Dong L. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta--nalysis[Oxford]. Rheumatology (Oxford)2019;kez380. doi:10.1093/rheumatology/kez380
17. Bektaş M, Ağargün BF, Torun ES et al. Pure Red Cell Aplasia in IgG4-Related Disease: Successful Treatment With Cyclosporine. J Clin Rheumatol. 2020 Dec 14. doi: 10.1097/RHU.0000000000001666. Epub ahead of print.
18. Yunyun F, Yu C, Panpan Z et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep. 2017;7(1):6195-6198.
19. Yunyun F, Yu P, Panpan Z et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology(Oxford). 2019;58(1):52-60. doi: 10.1093/rheumatology/key227.
20. Drobysheva A, Fuller J, Pfeifer CM, Rakheja D. Orbital Granulomatosis With Polyangiitis Mimicking IgG4-Related Disease in a 12-Year-Old Male. Int J Surg Pathol. 2018 Aug;26(5):453-458. doi: 10.1177/1066896917754252.
21. Luo X, Peng Y, Zhang P et al. Comparison of the Effects of cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study. Front Med (Lausanne). 2020 Jul 7;7:253. doi: 10.3389/fmed.2020.00253.
22. Yamamoto M. B cell targeted therapy for immunoglobulin G4-related disease. Immunol Med. 2021 Feb 14:1-7. doi: 10.1080/25785826.2021.1886630.
23. Khosroshahi A, Bloch DB, Deshpande V et al. JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010;62(6):1755-1762.
24. Khosroshahi A, Carruthers MN, Deshpande V et al. Rituximab for the treatment of IgG-4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57-66.
25. Carruthers MN, Topazian MD, Khosroshahi A et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum, DiS. 2015;74(6):1171–1177.
26. Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One 2017;12(9):e0183844. Published online 2017 Sep 15. doi: 10.1371/journal.pone.0183844
27. Backhus J, Neumann C, Perkhofer L et al. A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab. J Clin Med. 2021;10(6):1329. doi: 10.3390/jcm10061329.
28. Gu WJ, Zhang Q, Zhu J et. al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore) 2017;96(24):e6934.
29. Shao SAN, Chia-der LIN, Sheng-ta TSAI et al. Immunoglobulin G4-Related Disease Presented as Recurrent Otitis Media and Mixed Hearing Loss Treated With cyclophosphamide and Rituximab: Arch Rheumatol. 2019;34 (2):233–237.
30. Wu A, Andrew NH, Tsirbas A et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond) 2015;29 (1):122-128.
31. Aouidad I, Schneider P, Zmuda M et al. IgG4-Related Disease With Orbital Pseudotumors Treated With Rituximab Combined With Palpebral Surgery. JAMA Dermatol 2017; 153(3):355-356.
32. Berta AI, Agaimy A, Braun JM, et al. Bilateral Orbital IgG4-Related Disease with Systemic and Corneal Involvement Showing an Excellent Response to Steroid and Rituximab Therapy: Report of a Case with 11 Years Follow-Up. Orbit 2015;34(5): 299-301.
33. Caso F, Fiocco U, Costa L et al. Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine. 2014; 81(2):190-192.
34. Chen TS, Figueira E, Lau OC et al. Successful „medical" orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis. Ophthal Plast Reconstr Surg. 2014;30(5):e122-125.
35. Savino G, Battendieri R, Siniscalco A et al. Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports. Rheumatol Int. 2015;35(1): 183-188.,
36. Della-Torre E, Campochiaro C, Cassione EB et al. Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis. J Neurol Neurosurg Psychiatry2018; 89: 441-444. doi:10.1136/jnnp-2017-316519 pmid:28819060
37. Mageau A, Shor N, Fisselier M, et al. Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases. Pract Neurol. 2018;18(2):159-161. doi: 10.1136/practneurol-2017-001826.
38. Gu WJ, Zhang Q, Zhu J, et. al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore) 2017: 96(24 :e6934.)
39. Bullock DR, Miller BS, Clark HB, Hobday PM. Rituximab treatment for isolated IgG4-related hypophysitis in a teenage female. Endocrinol Diabetes Metab Case Rep. 2018;2018:18-0135. doi: 10.1530/EDM-18-0135. Epub 2018 Dec 28.
40. Boharoon H, Tomlinson J, Limback-Stanic C et al. A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab. J Endocr Soc. 2020 Apr 21;4(6):bvaa048. doi: 10.1210/jendso/bvaa048.
41. Mammen SV, Gordon MB. Succesful use of rituximab in case of Riedel thyreoiditis A resistant to treatment with prednisone and tamoxifem. AACE Clin Case Rep. 2019 Apr 25;5(3):e218-e221. doi: 10.4158/ACCR-2018-0352.
42. Jalilian C, Prince HM, McCormack C et al. IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review. Australas J Dermatol. 2014;55 (2):132-136.
43. Pomponio G, Olivari D, Mattioli M et al. Sustained clinical response after single course of rituximab as first-line monotherapy in adult-onset asthma and periocular xanthogranulomas syndrome associated with IgG4-related disease: A case report. Medicine (Baltimore). 2018;97(26):e11143. doi: 10.1097/MD.0000000000011143
44. Mochizuki H, Kato M, Higuchi T et al. Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions. Intern Med 2017;56 (9):1095-1099.
45. McMahon BA, Novick T, Scheel PJ et al. Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature. Medicine (Baltimore) 2015;94 (32) e1366.
46. Quattrocchio G, Barreca A, Demarchi A et al. IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. Oncotarget. 2018;9(30):21337–21347. doi: 10.18632/oncotarget.25095.
47. Eroglu E, Sipahioglu MH, Senel S et al. Successful treatment of tubulointerstitial nephritis in immunoglobulin G4-related disease with rituximab: A case report. World J Clin Cases. 2019;7(16):2309-2315. doi:
48. Lanzillotta M, Della-Torre E, Wallace ZS et al. Efficacy and safety of rituximab for IgG-4-related pancreato-biliary disease: A systematic review and meta-analysis. Pancreatology. 2021 Oct;21(7):1395-1401. doi:10.1016/j.pan.2021. 06. 009. Epub 2021 Jul 3. PMID: 34244040.
49. Gillispie MC, Thomas RD, Hennon TR. Successful treatment of IgG-4 related sclerosing disease with rituximab: a novel case report. Clin Exp Rheumatol 2015;33 (4):549-550.
50. Nikolic S, Panic N, Hintikka ES et al. Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature. Scand J Gastroenterol. 2021;56(11):1355-1362. doi: 10.1080/00365521.2021.1963837. Epub 2021 Aug 19.
51. Terumi Kamisawa, Takahiro Nakazawa, Susumu Tazuma, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019 Jan; 26(1): 9–42.
52. Peisen F, Thaiss WM, Ekert K et al. Retroperitoneal Fibrosis and its Differential Diagnoses: The Role of Radiological Imaging. Rofo. 2020;192(10):929-936. doi: 10.1055/a-1181-9205. Epub 2020 Jul 22. PMID:32698236.
53. Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: An update. Mod Rheumatol. 2019;29(2):231-239. doi:10.1080/14397595.2018.1554321. Epub 2019 Jan 8.
54. Forestier A, Buob D, Mirault T et al. No specific imaging pattern can help differentiate IgG4-related disease from idiopathic retroperitoneal fibrosis: 18 histologically proven cases. Clin Exp Rheumatol. 2018;36(3):371-375.
55. Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant. 2021;36(10):1773-1781.doi: 10.1093/ndt/gfaa083.
56. Wallwork R, Wallace Z, Perugino C et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). 2018;97(42):e12631. doi: 10.1097/MD.0000000000012631.
57. Boyeva V, Alabsi H, Seidman MA et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol. 2020;4:40. doi: 10.1186/s41927-020-00140-9. PMID: 32775962;
58. Almeqdadi M, Al-Dulaimi M, Perepletchikov A, et al. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: A case report and literature review. Clin Nephrol Case Stud. 2018 Apr 27;6:4-10. doi 10.5414/CNCS109321
59. Hamdan A, Moeen Z, Tariq H et al. An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab. Cureus. 2021 Sep 13;13(9):e17940. doi:10.7759/cureus.17940.
60. Rossi GM, Rocco R, Accorsi Buttini E et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. A. Intern Emerg Med. 2017;12:287–299.
61. Kermani TA, Crowson CS, Achenbach SJ. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011;86:297–303.
62. Marcolongo R, Tavolini IM, Laveder F et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med. 2004;116:194–197
63. Scheel PJ, Feeley N, Sozio SM Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011;154:31–36.
64. Marzano A, Trapani A, Leone N et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum, DiS. 2001;60:427–428.